Effects of M2000 (D-Mannuronic Acid) on Learning, Memory Retrieval, and Associated Determinants in a Rat Model of Alzheimer’s Disease

The d-mannuronic acid (M2000) is a novel nonsteroidal anti-inflammatory drug that has immunosuppressive effects together with antioxidant property. M2000 has shown a notable efficacy in experimental models of multiple sclerosis, rheumatoid arthritis, and nephrotic syndrome. In this work, the effect of M2000 on the treatment of Alzheimer’s disease (AD) was performed by Morris water maze experiment, and the immunological assessments were carried out by Western blot, apoptosis (procaspase-3, Bax/Bcl2, P53), enzymatic (superoxide dismutase [SOD]), and nonenzymatic oxidative stress (malondialdehyde [MDA]) tests. We found that pretreatment of AD in the rat model by M2000 had a potent efficacy on rat behavior and also it led to a significant inhibition of amyloid plaque production. Moreover, our data showed that M2000 can reduce the amount of Bax/Bcl2, P53, MDA, and SOD, as well as it normalized the level of procaspase-3. Our results suggest M2000 is a potential therapeutic agent for the treatment of AD.

[1]  D. Price,et al.  Role of the β‐amyloid protein in Alzheimer's disease , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  U. Müller,et al.  Differential regulation of toll-like receptor mRNAs in amyloid plaque-associated brain tissue of aged APP23 transgenic mice , 2009, Neuroscience Letters.

[3]  S. Cuzzocrea,et al.  M2000: a revolution in pharmacology. , 2005, Medical science monitor : international medical journal of experimental and clinical research.

[4]  E. Masliah,et al.  APP transgenic modeling of Alzheimer’s disease: mechanisms of neurodegeneration and aberrant neurogenesis , 2009, Brain Structure and Function.

[5]  D. Selkoe,et al.  Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration. , 2004, Protein and peptide letters.

[6]  Peter Eck,et al.  Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention , 2003, Journal of the American College of Nutrition.

[7]  P. Moreira,et al.  Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. , 2008, Free radical biology & medicine.

[8]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[9]  John Smythies.  Off the beaten track: the molecular structure of long-term memory: three novel hypotheses—electrical, chemical and anatomical (allosteric) , 2015, Front. Integr. Neurosci..

[10]  B. Mayer,et al.  Mitochondrial regulation of apoptosis. , 2003, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[11]  D. Butterfield,et al.  Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer’s amyloid β-peptide 1–42 , 2002, Peptides.

[12]  C. Holmes,et al.  Systemic inflammation and Alzheimer's disease. , 2011, Biochemical Society transactions.

[13]  E. Mazzon,et al.  Treatment of Experimental Arthritis with M2000, a Novel Designed Non‐Steroidal Anti‐Inflammatory Drug , 2005, Scandinavian journal of immunology.

[14]  Liang Zhou,et al.  Neuroprotective effects of Lycium barbarum polysaccharides in lipopolysaccharide-induced BV2 microglial cells. , 2013, Molecular medicine reports.

[15]  David P. Wolfer,et al.  Spatial Memory and Learning in Transgenic Mice: Fact or Artifact? , 1998, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[16]  Y. Kitamura,et al.  Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease , 1998, Brain Research.

[17]  Sung-Chun Tang,et al.  Toll-like receptors in neurodegeneration , 2009, Brain Research Reviews.

[18]  K. Blennow,et al.  Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers. , 2003, Clinica chimica acta; international journal of clinical chemistry.

[19]  C. Finch,et al.  Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? , 2001, Trends in Neurosciences.

[20]  B. Rehm,et al.  Novel Immunosuppressive Therapy by M2000 in Experimental Multiple Sclerosis , 2005, Immunopharmacology and immunotoxicology.

[21]  Kong-Joo Lee,et al.  Glucuronic acid is a novel inducer of heat shock response. , 2004, Molecular and cellular biochemistry.

[22]  M. Geng,et al.  Determination of the accessibility of acidic oligosaccharide sugar chain to blood-brain barrier using surface plasmon resonance. , 2006, Biological & pharmaceutical bulletin.

[23]  R. D'Hooge,et al.  Applications of the Morris water maze in the study of learning and memory , 2001, Brain Research Reviews.

[24]  D. Selkoe.  Amyloid β protein precursor and the pathogenesis of Alzheimer's disease , 1989, Cell.

[25]  R. Abhari,et al.  Therapeutic Approach by a Novel Designed Anti-Inflammatory Drug, M2000, in Experimental Immune Complex Glomerulonephritis , 2007, Immunopharmacology and immunotoxicology.

[26]  Maria M. M. Santos,et al.  Cell death targets and potential modulators in Alzheimer's disease. , 2010, Current pharmaceutical design.

[27]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[28]  M. Abdollahi,et al.  Preclinical assessment of β-d-mannuronic acid (M2000) as a non-steroidal anti-inflammatory drug , 2015, Immunopharmacology and immunotoxicology.

[29]  T. Montine,et al.  Free radical-mediated damage to brain in Alzheimer's disease and its transgenic mouse models. , 2008, Free radical biology & medicine.

[30]  F. Khodagholi,et al.  Alginate protects NT2 neurons against H2O2-induced neurotoxicity , 2010 .

[31]  H C Hendrie,et al.  Epidemiology of dementia and Alzheimer's disease. , 1998, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[32]  C. Vorhees,et al.  Morris water maze: procedures for assessing spatial and related forms of learning and memory , 2006, Nature Protocols.

[33]  Dae-Yeop Hwang,et al.  Alterations in behavior, amyloid p‐42, caspase‐3, and Cox‐2 in mutant PS2 transgenic mouse model of Alzheimer's disease , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[34]  Harald Hampel,et al.  Biological markers of amyloid β-related mechanisms in Alzheimer's disease , 2010, Experimental Neurology.

[35]  Paul W. Frankland,et al.  Frontiers in Integrative Neuroscience Integrative Neuroscience , 2022 .

[36]  I. Grundke‐Iqbal,et al.  Neurofibrillary pathology leads to synaptic loss and not the other way around in Alzheimer disease. , 2002, Journal of Alzheimer's disease : JAD.

[37]  P. Bickford,et al.  Blueberry opposes beta-amyloid peptide-induced microglial activation via inhibition of p44/42 mitogen-activation protein kinase. , 2008, Rejuvenation research.

[38]  Y. Niwa,et al.  Antioxidant activity of synovial fluid, hyaluronic acid, and two subcomponents of hyaluronic acid. Synovial fluid scavenging effect is enhanced in rheumatoid arthritis patients. , 1988, Arthritis and rheumatism.

[39]  C. Schild-Poulter,et al.  RanBPM Has Proapoptotic Activities That Regulate Cell Death Pathways in Response to DNA Damage , 2009, Molecular Cancer Research.

[40]  Jian Ding,et al.  Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms , 2005, Neuroscience Letters.

[41]  D. Jeste,et al.  Overview of depression and psychosis in Alzheimer's disease. , 1989, The American journal of psychiatry.

[42]  J. Trojanowski,et al.  “Fatal Attractions” of Proteins: A Comprehensive Hypothetical Mechanism Underlying Alzheimer's Disease and Other Neurodegenerative Disorders , 2000, Annals of the New York Academy of Sciences.

[43]  P. Mecocci,et al.  Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment , 2009, Ageing Research Reviews.

[44]  N. Braidy,et al.  Neuroprotective Effect of Natural Products Against Alzheimer’s Disease , 2012, Neurochemical Research.

[45]  A. LeBlanc,et al.  Amyloid β Peptide of Alzheimer’s Disease Downregulates Bcl-2 and Upregulates Bax Expression in Human Neurons , 1996, The Journal of Neuroscience.

[46]  Kehkashan Parveen,et al.  Selenium prevents cognitive decline and oxidative damage in rat model of streptozotocin-induced experimental dementia of Alzheimer's type , 2009, Brain Research.

[47]  T. Bird.  Genetic factors in Alzheimer's disease. , 2005, The New England journal of medicine.